Despite biosimilars being available for over ten years in some markets, the biosimilars market continues to evolve. Development of biosimilars is a truly global endeavour, helped by the spread of regulatory guidance. In this white paper, we explore the biosimilar R&D landscape, physician attitudes towards biosimilars, and drivers to prescribe, as well as two case studies on the launch dynamics of Sandoz’s Zarxio and Pfizer’s Inflectra in the United States.

Pivoting a product launch during the pandemic

View Now